A Virtual Reality View: New Approaches to the Diagnosis and Treatment of Pediatric and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis

THURSDAY, May 28, 2020

08:00 – 09:00 AM CT

09:00 AM Eastern; 08:00 AM Central; 07:00 AM Mountain; 06:00 AM Pacific

Activity Description

While guidelines regarding the management of AD in children have been published, variability persists in practice. Treatment inconsistencies and the chronic and relapsing nature of AD can lead to frustration for patients, family, and caregivers when managing AD. This program will focus on providing AD caregivers an update on recent pathophysiological findings that drive new therapeutic targets; reviewing severity and diagnosis of AD; and discussing the clinical profiles of existing and emerging agents, with focus on treatment individualization.

Target Audience

This activity is intended for US-based pediatric/adolescent dermatologists, allergists/immunologists and other health care professionals who diagnose and manage pediatric/adolescent patients with moderate-to-severe AD.

Educational Objectives

Upon the completion of this program, attendees should be able to:

  • Apply updated diagnostic guidance for pediatric and adolescent patients with moderate-to-severe AD and use severity assessments to inform management decisions
  • Review the clinical profiles and mechanisms of action of newly approved and emerging systemic/biologic agents for the treatment of pediatric and adolescent patients with moderate-to-severe AD
  • Explain the benefits associated with patient centered, team-based shared decision-making approaches for the management of moderate-to-severe AD in children and adolescents

Disclosure Policy Statement

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

Disclosure of Conflicts of Interest

Amy S. Paller, MD, has nothing to disclose.

Peter A. Lio, MD, has received grants as an investigator and/or honoraria for lecturing, and/or consulting fees from: Eli Lilly, UCB, Dermavant, Regeneron/Sanofi Genzyme, Dermira, Pfizer, LEO Pharmaceuticals, AbbVie, Kiniksa, La Roche Posay/L’Oreal, Pierre-Fabre, Johnson & Johnson, Unilever, Menlo Therapeutics, Theraplex, IntraDerm, Exeltis, AOBiome, Realm Therapeutics, Franklin Bioscience/Altus Labs, Verrica, TopMD, Arbonne, Burt’s Bees, and the National Eczema Association.

The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.

The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group has nothing to disclose.
Diana Tommasi, Medical Services for Med Learning Group, has nothing to disclose.
Ana Maria Albino, Program Manager for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.

Accreditation Statement

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.

Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

Purpose: This program would be beneficial for nurses involved in the care of patients with AD. CNE Credits: 1.0 ANCC Contact Hours.

CNE Accreditation Statement: Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hours of continuing nursing education of RNs and APNs.



Disclosure of Unlabeled Use

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.


Med Learning Group makes every effort to develop CME activities that are science based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

Method of Participation and Request for Credit

There are no fees for participating and receiving CME credit for this live activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the live activity.
  3. Submit the evaluation form to Med Learning Group.

You will receive your certificate within 60 days of evaluation submission.

Contact Information for Questions About the Activity


System Requirements

Performedia requires a modern web browser (Microsoft Edge, Mozilla Firefox, Apple Safari, Google Chrome). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software.

Release date: May 28, 2020
Expiration date: May 28, 2020
Estimated time to completion: 1.0 hour